Commensal Gut-Derived Anaerobes as Novel Therapy for Inflammatory Autoimmune Diseases
Abstract
Rheumatoid arthritis (RA) and multiple sclerosis (MS) are chronic inflammatory autoimmune diseases affecting millions of people. Here we are proposing a novel approach to cure MS, by administration of a specific strain of human commensal-bacteria. Recent studies have shown that intestinal microflora plays an important role in the health of the host and posses probiotics like qualities. We hypothesize that Gram-negative commensal bacteria from human gut have the potential to be used as a therapeutic agent. We have used collagen induced arthritis (CIA) in HLA-DR4DQ8 mice and PLP91-110 induced experimental autoimmune encephalomyelitis (EAE) HLA-DR3DQ8 mice to test our hypothesis that treatment with commensal bacteria Prevotella histicola can modulate disease. First using various doses of bacteria, we have identified the optimal dose to be used for treatment of CIA as well as EAE. Treatment of mice with P histicola as probiotics is ongoing. Our study showed that treatment of mice with 3-4 doses of P. histicola in collagen/PLP91-110-immunized mice led to suppression of antigen-specific immune response in-vitro in both CIA as well as EAE model. Our data indicates that P histicola induced immune responses in the gut cause induction of immune tolerance in periphery leading to suppression of antigen specific response.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2011
- Accession Number
- ADA550807
Entities
People
- Ashutosh Mangalam
Organizations
- Mayo Clinic